Pictet Asset Management Ltd. increased its position in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 12.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 480,013 shares of the biopharmaceutical company’s stock after buying an additional 52,124 shares during the period. Pictet Asset Management Ltd.’s holdings in Sage Therapeutics were worth $31,734,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Handelsbanken Fonder AB bought a new position in Sage Therapeutics during the first quarter worth $1,279,000. Bank of New York Mellon Corp increased its position in Sage Therapeutics by 189.3% in the first quarter. Bank of New York Mellon Corp now owns 2,056,895 shares of the biopharmaceutical company’s stock worth $146,183,000 after buying an additional 1,345,829 shares during the period. DekaBank Deutsche Girozentrale increased its position in Sage Therapeutics by 122.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 73,450 shares of the biopharmaceutical company’s stock worth $4,762,000 after buying an additional 40,400 shares during the period. Emerald Advisers Inc. PA bought a new position in Sage Therapeutics during the first quarter worth $10,306,000. Finally, Emerald Mutual Fund Advisers Trust bought a new position in Sage Therapeutics during the first quarter worth $7,139,000.

Sage Therapeutics, Inc. (SAGE) opened at 85.67 on Thursday. The firm’s market capitalization is $3.20 billion. Sage Therapeutics, Inc. has a 52-week low of $35.02 and a 52-week high of $90.43. The firm’s 50-day moving average is $81.82 and its 200 day moving average is $69.84.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by $0.25. During the same quarter in the previous year, the business posted ($1.08) EPS. Equities analysts anticipate that Sage Therapeutics, Inc. will post ($7.38) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Pictet Asset Management Ltd. Increases Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)” was reported by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/08/10/pictet-asset-management-ltd-increases-stake-in-sage-therapeutics-inc-nasdaqsage.html.

A number of equities analysts have recently weighed in on the stock. Cowen and Company reaffirmed a “buy” rating and issued a $100.00 price target on shares of Sage Therapeutics in a research note on Friday, August 4th. Canaccord Genuity set a $110.00 price target on shares of Sage Therapeutics and gave the stock a “buy” rating in a research note on Saturday, August 5th. Stifel Nicolaus assumed coverage on shares of Sage Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $104.00 price target on the stock. Leerink Swann reaffirmed an “outperform” rating and issued a $97.00 price target (up from $90.00) on shares of Sage Therapeutics in a research note on Tuesday, June 20th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $82.00 price target on shares of Sage Therapeutics in a research note on Friday, July 28th. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $89.64.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sage Therapeutics, Inc. (NASDAQ:SAGE).

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.